Key Developments: Accelerate Diagnostics Inc (AXDX.O)

AXDX.O on Consolidated Issue listed on NASDAQ Capital Market

21.82USD
5 May 2015
Change (% chg)

-- (--)
Prev Close
$21.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
195,978
52-wk High
$31.86
52-wk Low
$15.37

Search Stocks

Latest Key Developments (Source: Significant Developments)

Accelerate Diagnostics Inc achieves ISO 13485 certification and initial installations of accelerate ID/AST system
Monday, 16 Mar 2015 02:15pm EDT 

Accelerate Diagnostics Inc:Receives ISO 13485:2003 certification for its quality management system and began manufacturing and installing GMP compliant systems at select study sites.Says it will seek FDA clearance of Accelerate ID/AST System and associated test for positive blood cultures upon successful completion of an upcoming clinical trial.  Full Article

Accelerate Diagnostics announces research collaboration with CDC Laboratory for early detection of antibiotic-resistant biothreat agents
Monday, 3 Nov 2014 01:51pm EST 

Accelerate Diagnostics, Inc:Enters into research collaboration with Rapid Antimicrobial Susceptibility Testing Laboratory at U.S. Centers for Disease Control and Prevention (CDC).To develop tests for rapid analysis of antibiotic-resistant biothreat agents based on Accelerate's high-speed identification and antibiotic susceptibility testing platform.  Full Article

Accelerate Diagnostics announces final results of rights offering
Friday, 2 May 2014 12:24pm EDT 

Accelerate Diagnostics Inc:Completed its previously announced rights offering.Raised $45,000,000 from the rights offering.Subscribed for a total of 1,517,880 shares of the company's common stock pursuant to their subscription privileges, yielding a total of $25,500,391, of which 692,705 shares, or 58 pct, were subscribed for by directors of the company.  Full Article

Accelerate Diagnostics commences rights offering
Monday, 7 Apr 2014 02:43pm EDT 

Accelerate Diagnostics Inc:Commences a $45,000,000 rights offering to fund its product commercialization efforts.Intends to issue 2,678,571 shares of common stock in connection with the rights offering.  Full Article

Accelerate Diagnostics Inc Announces Final Results of Rights Offering
Tuesday, 13 Aug 2013 10:58am EDT 

Accelerate Diagnostics Inc announced that it has completed its previously announced rights offering. Through broad participation from both insiders and non-insider investors, the Company raised $20,000,000, including proceeds from a standby commitment made by Abeja Ventures, LLC. Stockholders subscribed for a total of 1,871,410 shares of the Company's common stock pursuant to their basic subscription privileges, representing a 75% participation rate. In addition, stockholders over subscribed for a total of 1,077,471 shares of which 203,062 shares were issued following exclusions based on the outcome of the basic subscription. Finally, a total of 413,090 shares of common stock will be issued to the standby purchaser. In the aggregate, the Company will issue 2,487,562 shares of common stock of which 1,719,425 shares, or 69%, were acquired by directors of the company.  Full Article

Accelerate Diagnostics Inc Announces Final Terms Of Rights Offering
Friday, 12 Jul 2013 08:00am EDT 

Accelerate Diagnostics, Inc. announced that the final terms of its previously announced $20,000,000 rights offering. The Company anticipates that the rights offering will commence with the distribution of the final prospectus and related materials to stockholders on or about July 18, 2013. Under the terms of the rights offering, the Company is distributing, at no charge to the holders of its common stock as of on July 8, 2013, which was established as the record date for the rights offering, 0.064038 non-transferable subscription rights for each share of common stock owned on the record date, as more fully described in the prospectus relating to the rights offering. Each whole subscription right will allow the holder thereof to subscribe to purchase one share of common stock at a subscription price of $8.04 per share. In addition, any holder of subscription rights exercising his, her or its basic subscription privilege in full will be eligible to subscribe to purchase additional shares of common stock at the same subscription price per share, subject to the conditions and limitations described further in the prospectus. In the aggregate, the Company intends to issue up to 2,487,562 shares of common stock in connection with the rights offering.  Full Article

Accelerate Diagnostics Inc Announces Plans For Rights Offering To Stockholders
Tuesday, 4 Jun 2013 06:02am EDT 

Accelerate Diagnostics Inc announced that it has filed a Registration Statement on Form S-3 with the Securities and Exchange Commission (the SEC) for a rights offering to existing holders of common stock. Upon completion of the rights offering, the Company will receive gross proceeds of approximately $20,000,000 before expenses. The Company has received a standby commitment from Abeja Ventures, LLC, which is owned by, among other individuals and entities, Lawrence Mehren, John Patience, Jack Schuler and Matthew W. Strobeck, each of whom is a director of the Company. The standby purchaser has agreed to purchase any and all shares of common stock that are not subscribed for by stockholders in connection with the rights offering. The rights offering will be made through the Company's distribution to existing stockholders of non-transferable subscription rights to purchase their pro rata portion of newly issued shares of the Company's common stock. The subscription price has not yet been determined but will be based on the closing market price of the Company's common stock. The net proceeds of the offering will be used for working capital and specifically to fund the Company's business plan and product commercialization efforts.  Full Article

No consensus analysis data available.
Search Stocks